Sonoma Pharmaceuticals increases ATM offering capacity by $785,679

Sonoma Pharmaceuticals, Inc.

Amendment No. 1 to Dec 2023 Equity Distribution Agreement with Maxim Group LLC allows sale of up to $785,679 in additional common shares.
Shares will be sold under existing effective S-3 registration statement (File No. 333-275311) and a prospectus supplement filed March 8, 2024.
No specific use of proceeds disclosed; prior ATM offerings typically used for working capital and general corporate purposes.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Sonoma Pharmaceuticals, Inc. amended Amendment No. 1 with Maxim Group LLC valued at up to $785,679 (effective 2024-03-08).

Action: amendment
Agreement: atm program
Counterparty: Maxim Group LLC
Value: up to $785,679
Effective: 2024-03-08

Exact text from the filing

On March 8, 2024, the Company entered into an amendment to the Agreement (“Amendment No. 1”) to provide for the sale of up to $785,679 of additional shares under the Agreement.

View on SEC.gov

589 material agreements filed in the last 30 days. Browse all material agreements →

Sonoma Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-24-001399

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.